<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01302925</url>
  </required_header>
  <id_info>
    <org_study_id>LP0041-01</org_study_id>
    <nct_id>NCT01302925</nct_id>
  </id_info>
  <brief_title>PEP005 Gel - Evaluation of Local Tolerability After Exposure to Ingenol Mebutate Gel Followed by Hand Washing in Healthy Subjects</brief_title>
  <official_title>PEP005 Gel - Evaluation of Local Tolerability After Exposure to Ingenol Mebutate 0.05% and 0.015% Gel Followed by Hand Washing in Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peplin</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peplin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this phase 1 trial is to investigate the local tolerability on the finger
      following exposure to PEP005 Gel 0.015% or 0.05% and hand washing once daily, for 2 or 3
      consecutive days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local Skin Responses</measure>
    <time_frame>Up to 8 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Healthy</condition>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>PEP005 Gel 0.05%/2 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be exposed to investigational product for 2 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEP005 Gel 0.015%/3 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be exposed to investigational product for 3 consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEP005 Gel</intervention_name>
    <description>PEP005 Gel 0.05% for 2 consecutive days</description>
    <arm_group_label>PEP005 Gel 0.05%/2 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEP005 Gel</intervention_name>
    <description>PEP005 Gel 0.015% for 3 consecutive days</description>
    <arm_group_label>PEP005 Gel 0.015%/3 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be male or female and at least 18 years of age

          -  Female patients must be of: non-childbearing potential or if of childbearing potential
             then have a negative serum and urine pregnancy test and using effective contraception

          -  Ability to provide informed consent

        Exclusion Criteria:

          -  Have received treatment with immunomodulators, or interferon/interferon inducers or
             systematic medications that suppress the immune system in the last 4 weeks

          -  Exposed to prescribed systemic (take as tablet, injection etc) or topical (gel, cream,
             lotion) medication within the last 7 days

          -  Have any signs of skin irritation or damaged skin at or around the dominant index
             finger

          -  Have worked in an occupation with a high risk of being in contact with irritative
             material (eg. chemicals, painting) on their hands, especially fingers

          -  Those who are currently participating in any other clinical trial

          -  Those known or suspected of not being able to comply with the requirements of the
             protocol

          -  Females who are pregnant or are breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Dosik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>TKL Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TKL Research</name>
      <address>
        <city>Paramus</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.leo-pharma.com/Home/Research-and-Development/Clinical-trial-disclosure/Clinical-trial-summaries-and-reports.aspx</url>
    <description>Clinical Trials at LEO Pharma</description>
  </link>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2011</study_first_submitted>
  <study_first_submitted_qc>February 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2011</study_first_posted>
  <last_update_submitted>September 11, 2015</last_update_submitted>
  <last_update_submitted_qc>September 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2015</last_update_posted>
  <responsible_party>
    <name_title>Rikke L Fischer/International Clinical Trial Manager</name_title>
    <organization>LEO Pharma</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

